Trial Profile
A two-arm phase II randomised trial of intermittent chemotherapy plus continuous cetuximab and of intermittent chemotherapy plus intermittent cetuximab in first line treatment of patients with K-ras-normal (wild-type) metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Levofolinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms COIN-B
- 19 Jun 2023 Results of pooled analysis data pooled analysis of Valentino, Panama, MACRO-2, COIN-B trials published in the European Journal of Cancer
- 01 Nov 2021 Results of pooled analysis from MRC-COIN and COIN-B trials assessing Genome-wide association studies of toxicity published in the International Journal of Cancer
- 17 Jan 2021 Results of pooled analysis assessing tumor bulk as a predictive biomarker to anti-EGFR therapy by using data from two studies (COIN and COIN B) presented at the 2021 Gastrointestinal Cancers Symposium